https://www.selleckchem.com/pr....oducts/etomoxir-na-s
In the HLA screening group, 28 out of 192 patients (14.6%) tested HLA-B*5801 positive were advised to avoid allopurinol; 156 out of 164 HLA-B*5801-negative patients received allopurinol and none developed SCARs. The incidence rate of SCARs was significantly lower in the HLA screening group compared with controls (0% vs 2.14% respectively, p = 0.037*). The targeted HLA screening approach was associated with lower healthcare costs compared with no HLA screening (US$ 92,430 vs US$ 281,226). Pre-treatment HLA-B*5801 screening is co
Like
Comment
Share
